Lieve Lucille Adriaens

Title: Lieve Lucille Adriaens: Innovator in Cancer Treatment

Introduction

Lieve Lucille Adriaens is a prominent inventor based in Westfield, NJ (US). She has made significant contributions to the field of cancer treatment, particularly in the development of innovative therapeutic methods for multiple myeloma. With a total of 2 patents, her work is paving the way for advancements in immunotherapy.

Latest Patents

Adriaens' latest patents include groundbreaking methods for treating multiple myeloma using bispecific anti-BCMA x anti-CD3 antibodies. This invention focuses on the use of bispecific antibodies that bind to both B-cell maturation antigen (BCMA) and CD3, activating T cells in the presence of BCMA-expressing tumor cells. Additionally, she has developed a dosing strategy that mitigates cytokine release syndrome for therapeutic antibodies. This method involves initial fractional dosing and the optional use of additional agents to manage potential adverse reactions during treatment.

Career Highlights

Lieve Lucille Adriaens is currently associated with Regeneron Pharmaceuticals, Inc., where she continues to innovate in the field of cancer therapies. Her work is characterized by a commitment to improving patient outcomes through advanced treatment methodologies.

Collaborations

Throughout her career, Adriaens has collaborated with notable colleagues, including Israel Lowy and David Sternberg. These partnerships have further enhanced her research and development efforts in the pharmaceutical industry.

Conclusion

Lieve Lucille Adriaens is a trailblazer in the field of cancer treatment, with her innovative patents and dedication to improving therapeutic strategies. Her contributions are vital in the ongoing fight against multiple myeloma and showcase the importance of innovation in medicine.